PROQR THERAPEUTICS Ownership

Stocks . Germany . 
Stock . PROQR THERAPEUTICS EO 04
0PQ Stock  EUR 3.40  0.01  0.29%   
PROQR THERAPEUTICS owns a total of 71.43 Million outstanding shares. PROQR THERAPEUTICS has large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as PROQR THERAPEUTICS in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of PROQR THERAPEUTICS, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in PROQR THERAPEUTICS EO 04. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

PROQR Stock Ownership Analysis

About 21.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 0.92. PROQR THERAPEUTICS had not issued any dividends in recent years. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany. For more info on PROQR THERAPEUTICS EO 04 please contact Daniel Boer at 31 88 166 7000 or go to http://www.proqr.com.

PROQR THERAPEUTICS Outstanding Bonds

PROQR THERAPEUTICS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PROQR THERAPEUTICS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PROQR bonds can be classified according to their maturity, which is the date when PROQR THERAPEUTICS EO 04 has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Boeing Co 2196 Corp Bond
US097023DG73		View
BNP Paribas FRN Corp Bond
USF1R15XK367		View
AerCap Global Aviation Corp Bond
US00773HAA59		View

Currently Active Assets on Macroaxis

TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft
HBIHanesbrands
STLDSteel Dynamics

Other Information on Investing in PROQR Stock

PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY